← boardnext 2027-07next 2028-02-28
MESO
Mesoblast, Ltd.distress 3/10 · well-funded / low risk$15.97-2%today-24% from 52w high
Lead: GVHD - Graft-Versus-Host Disease
Revenue
$17M
Liquidity
$131M
Runway
2.6 yrs
Shares 1y
+165%
Price & events
-14.9% over 6M
CatalystRating changeDilutionFinancingdashed = today
-2.0%
1D
-10.6%
1W
+3.8%
1M
+3.0%
3M
-13.1%
6M
-0.7%
1Y
+93.1%
2Y
+10.0%
5Y
-6.2%
All
Overview
- Market Cap
- $20.44B
- Enterprise Value
- $20.37B
- Volume
- 9.68K
- 52 Week Range
- $10.96 – $20.96
- Total Shares
- 1.28B
- Float Shares
- 82.40M
- Short %
- 3.29%
- % Held by Insiders
- 5.04%
- % Held by Institutions
- 2.80%
- RVOL
- 0.04x
- Beta
- 0.80
Pipeline stages · 2 programs
Rexlemestrocel-L, HA mixture
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Remestemcel-L-rknd
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 2 trials · 2 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-07 Estimated 50% readout ~2027-09-14 | Phase 3 | Rexlemestrocel-L, HA mixture | Degenerative Disc Disease | — | active not recruiting |
| 2028-02-28 Estimated 50% readout ~2028-05-13 | Phase 3 | Remestemcel-L-rknd | GVHD - Graft-Versus-Host Disease | — | not yet recruiting |
Catalyst news & presentations · 0
- No catalyst news yet.
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
buy · target $35 (+119% upside) · 2 analysts
- 2025-11-25JefferiesHold → Buy
- 2025-07-18JefferiesBuy → Hold
- 2025-02-07Piper SandlerOverweight
- 2024-12-23JefferiesBuy → Hold
- 2024-12-19Piper SandlerOverweight
- 2024-07-23Piper SandlerNeutral → Overweight
Competitors — GVHD - Graft-Versus-Host Disease
- none identified
Recent news
- 2026-07-23Mesoblast (ASX:MSB) Dips Today — Should Investors Be Watching This Cell Therapy Biotech? - Kalkine
- 2026-07-21Mesoblast (NASDAQ: MESO) CEO invests A$2,733,734 to exercise options - Stock Titan
- 2026-07-17What Triggered Today's Move in the Mesoblast (ASX:MSB) Share Price? - Kalkine
- 2026-07-16Bell Potter Maintains MESOBLAST LTD(MEOBF.US) With Buy Rating, Raises Target Price to $3.08 - 富途牛牛
- 2026-07-16Mesoblast (ASX:MSB) Moves Higher — Tracking the Biotech's Clinical and Commercial Progress - Kalkine
- 2026-07-15Mesoblast Limited (MESO) sees 278,571 director options lapse in July - Stock Titan
- 2026-07-14Mesoblast (NASDAQ: MESO) reaches 300 patients in Phase 3 CLBP trial - Stock Titan
- 2026-07-14Australia's Mesoblast reaches target of 300 trial patients - grafa.com
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.